title: Emerging therapeutics targeting mRNA translation.
abstract: A defining feature of many cancers is deregulated translational control. Typically, this occurs at the level of recruitment of the 40S ribosomes to the 5'-cap of cellular messenger RNAs (mRNAs), the rate-limiting step of protein synthesis, which is controlled by the heterotrimeric eukaryotic initiation complex eIF4F. Thus, eIF4F in particular, and translation initiation in general, represent an exploitable vulnerability and unique opportunity for therapeutic intervention in many transformed cells. In this article, we discuss the development, mode of action and biological activity of a number of small-molecule inhibitors that interrupt PI3K/mTOR signaling control of eIF4F assembly, as well as compounds that more directly block eIF4F activity.
authors.affiliation: Department of Biochemistry and McGill University, Montréal, Québec H3G 1Y6, Canada.
authors.forename: Abba
authors.initials: A
authors.lastname: Malina
authors.forename: John R
authors.initials: JR
authors.lastname: Mills
authors.forename: Jerry
authors.initials: J
authors.lastname: Pelletier
mesh_terms: D039562:Eukaryotic Initiation Factor-4F / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D014176:Protein Biosynthesis; D012333:RNA, Messenger / Q000235:genetics*
chemical_list: D039562:Eukaryotic Initiation Factor-4F; D012333:RNA, Messenger